In the supplied oncology record, Carfilzomib is associated with Multiple Myeloma, particularly in the settings described as Relapsed/refractory multiple myeloma in combination regimens or monotherapy in selected settings. Its pharmacological class is Irreversible proteasome inhibitor. Irreversibly inhibits proteasomal chymotrypsin-like activity, promoting proteotoxic stress and apoptosis. Proteasome inhibition targets a cellular process on which malignant plasma cells and selected lymphoid tumors can be particularly dependent. The treatment category is recorded as Targeted Therapy; Proteasome Inhibitor. Regimen examples include KRd; Kd; Isa-Kd and other myeloma combinations. Rather than implying one universal use, these combinations show the range of contexts in which the medicine may be incorporated. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. The clinical significance of the drug is best understood through the disease-specific indication: stage, histology, treatment history, and any molecular or receptor requirement may influence eligibility. Where the same agent is listed for more than one cancer, its role should not be assumed to be interchangeable between diseases. This summary is intentionally non-prescriptive and does not include individualized dosing. Current labeling and relevant disease guidance should be reviewed when the database is used for clinical decision support.